Format

Send to

Choose Destination
Leukemia. 2015 Sep;29(9):1832-8. doi: 10.1038/leu.2015.168. Epub 2015 Jun 29.

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.

Author information

1
Cancer Theme, SAHMRI, Division of Haematology, SA Pathology, University of Adelaide, Adelaide, South Australia, Australia.
2
University of Turin, Orbassano, Italy.
3
MD Anderson Cancer Center, Houston, TX, USA.
4
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
5
Department of Hematology and Cancer Research Institute, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
6
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
7
Bristol-Myers Squibb, Princeton, NJ, USA.
8
Department of Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany.

Abstract

BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as first-line treatment of chronic myeloid leukemia in chronic phase (CML-CP). Less is known about mutation development during first-line treatment with dasatinib and nilotinib, despite increased use because of higher response rates compared with imatinib. Retrospective analyses were conducted to characterize mutation development in patients with newly diagnosed CML-CP treated with dasatinib (n=259) or imatinib (n=260) in DASISION (Dasatinib versus Imatinib Study in Treatment-Naive CML-CP), with 3-year minimum follow-up. Mutation screening, including patients who discontinued treatment and patients who had a clinically relevant on-treatment event (no confirmed complete cytogenetic response (cCCyR) and no major molecular response (MMR) within 12 months; fivefold increase in BCR-ABL1 with loss of MMR; loss of CCyR), yielded a small number of patients with mutations (dasatinib, n=17; imatinib, n=18). Dasatinib patients had a narrower spectrum of mutations (4 vs 12 sites for dasatinib vs imatinib), fewer phosphate-binding loop mutations (1 vs 9 mutations), fewer multiple mutations (1 vs 6 patients) and greater occurrence of T315I (11 vs 0 patients). This trial was registered at www.clinicaltrials.gov as NCT00481247.

PMID:
26118315
PMCID:
PMC4559757
DOI:
10.1038/leu.2015.168
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center